Stop type 1 diabetes: a drug delays its onset

Stop type 1 diabetes: a drug delays its onset

It is an advance of relevance for those who suffer from the disease / web

Medicine is constantly advancing and in the last few hours one of the most anticipated news was released, the approval of a drug capable of delaying the progression of type 1 diabetes.

The novelty came from the United States Food and Drug Administration (FDA) and was highly celebrated since it is a disease that occurs to a greater extent in children and adolescents.

As confirmed by the FDA, injections of the drug teplizumab may delay the onset of stage 3 type 1 diabetes in adults and in pediatric patients older than 8 years who currently have stage 2 type 1 diabetes.

While the drug does not prevent or cure the onset of type 1 diabetes, it does significantly delay its diagnosis by giving patients up to two years of disease-free lapse.

As confirmed by Kevan Herold, a researcher at the American Yale University, at the moment the longest delay was recorded in a patient who presented the disease just 11 years later.

What does the treatment consist of?

The specialists reported that the treatment lasts for 14 consecutive days in which patients receive a daily dose of the drug intravenously.

Once teplizumab is injected into patients with diabetes, it binds to certain cells of the immune system, slowing the progression to stage 3 type 1 diabetes.

The clinical trials involved 76 patients, some receiving the drug and others a placebo. The results showed that 45% of the 44 patients who received teplizumab were subsequently diagnosed with stage 3 type 1 diabetes, compared with 72% of the 32 patients who received a placebo.

From the time the medication was applied to the patients until the diagnosis of stage 3 type 1 diabetes, 50 months elapsed, while in those who did not receive the medication the disease appeared at 25 months.

Once the results were obtained, the regulatory agency approved it and qualified it as an “innovative treatment.”

In this sense, Dr. John Sharretts, a member of the entity in charge of the regulation, stated that “it adds an important new treatment option for certain patients at risk.” He further highlighted “the drug’s potential to delay the clinical diagnosis of type 1 diabetes can provide patients with months or years without the burden of disease.”

The symptoms

Although it can occur at any stage of life, type 1 diabetes is most often diagnosed in children and primarily young adults.

That is why the specialists recommended being attentive to the symptoms and consulting when adolescents present weight loss for no apparent reason; they feel hungry or tired; very thirsty; they urinate frequently; have sores that are slow to heal; dry and itchy skin; loss of sensation or tingling in the feet and blurred vision.

On the other hand, they pointed out that although most patients with type 1 diabetes do not have a family history, people who have a parent, brother or sister with type 1 diabetes are at higher risk of contracting the disease.

Teplizumab is manufactured by the Provention Bio laboratory, and together with Sanofi they will begin marketing in the United States.

According to estimates, the drug will be ready by the end of this year and the cost of the vial medication will be around $13,850, while the 14-day treatment will cost $193,900.

Despite the excitement caused by the discovery, patients in Argentina will have to wait since for the moment they will only be marketed in the United States.

Type 1 diabetes is most often diagnosed in children and young adults.

Leave a Comment